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Small-cell lung cancer (SCLC) is an aggressive tumor with a dismal prognosis 
among primary lung cancers. MicroRNAs (miRNAs) can act as oncogenes or 
tumor-suppressor genes in human malignancy.  The miR-34 family is comprised of 
tumor-suppressive miRNAs, and its reduced expression by methylation has been 
reported in various cancers, including non-small cell lung cancer (NSCLC).  In this 
study, we investigated the alteration and tumor-suppressive impact of miR-34s in SCLC.  
The methylation of miR-34a and miR-34b/c was observed in 4 (36 %) and 7 (64 %) of 
11 SCLC cell lines, respectively.  Among the 27 SCLC clinical specimens, miR-34a 
and miR-34b/c were methylated in 4 (15 %) and 18 (67 %), respectively.  In contrast, 
13 (28 %) miR-34a methylated cases and 12 (26 %) miR-34b/c methylated cases were 
found in 47 NSCLC primary tumors.  The frequency of miR-34b/c methylation was 
significantly higher in SCLC than in NSCLC (p < 0.001).  The expressions of miR-34s 
were reduced in methylated cell lines and tumors and restored after 
5-aza-2’-deoxycytidine treatment, indicating that methylation was responsible for the 
reduced expression of miR-34s.  Because the frequency of methylation was higher in 
miR-34b/c, we focused on miR-34b/c for a functional analysis.   We examined the 
effect of miR-34b/c introduction on cell proliferation, migration and invasion. The 
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transfection of miR-34b/c to two SCLC cell lines (H1048 and SBC5) resulted in the 
significant inhibition of cell growth, migration, and invasion, compared with control 
transfectants.  Our results indicate that the aberrant methylation of miR-34b/c plays an 
important role in the pathogenesis of SCLC, implying that miR-34b/c may be a useful 






Lung cancer is the leading cause of cancer-related death in the world at present. 
Small-cell lung cancer (SCLC) is an aggressive tumor with a dismal prognosis among 
primary lung cancers and accounts for approximately 13 % of all lung cancers [1, 2]. 
Chemotherapy or chemoradiotherapy is generally the treatment of choice for SCLC 
patients because the clinical features of SCLC include a high rate of metastasis to lymph 
nodes and distant organs beginning at an early stage.  A strong initial response but 
early acquired resistance to chemotherapeutic agents is a unique feature of SCLC [3, 4], 
resulting in a poor prognosis and a 5-year survival rate of only 5 % [5].  Thus, the 
development of new therapeutic strategies is mandatory. 
The understanding of molecular pathogenesis is crucial for the development of 
new therapeutic strategies for malignant tumors.   Of note, the profile of molecular 
alterations is quite different among the histological subtypes of lung cancer [6-8].  For 
example, epidermal growth factor receptor (EGFR) mutations [9], K-ras mutations and 
P16 methylation [8] are frequently found in non-small cell lung cancer (NSCLC), but 
not in SCLC [10].  In contrast, TP53 mutations [8, 11] or RASSF1A methylation [12] is 
frequently found in SCLC, compared with NSCLC.  These results indicate that the 
molecular pathogenesis differs between SCLC and NSCLC. 
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Many studies have shown that microRNAs (miRNAs) can act as oncogenes or 
tumor suppressors and that the widespread alteration of miRNA expression patterns is 
highly relevant to various human malignancies [13].  In lung cancer, the reduced 
expression of let-7 [14] or the overexpression of miR-155 [15] is reportedly correlated 
with the clinical outcome of NSCLC. The members of the miR-34 family consist of 
three miRNAs (miR-34a, 34b and 34c), the target genes of which are considered to be 
similar to one another but with some notable differences [17].  miR-34a is located on 
chromosome 1q36.22, while miR-34b and 34c (miR-34b/c) are located on chromosome 
11q23 and are generated by the processing of a single transcript [17].  A previous study 
indicated that miR-34 methylation was present in NSCLC and was significantly related 
to an unfavorable clinical outcome [18].  In a functional analysis the introduction of 
miR-34b/c into NSCLC suppressed the cell proliferation of NSCLC [19].  However, 
these studies examining the roles of miRNA in lung cancer have been mainly performed 
for NSCLC, and miRNA alterations and their impact on SCLC have not been 
investigated.   
In this study, we investigated miR-34 methylation in SCLC and found that 
miR-34b/c was frequently methylated in SCLC, compared with NSCLC.  Subsequently, 
we investigated the biological impact of miR-34b/c methylation on SCLC to understand 
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the role of miR-34b/c in the tumorigenesis of SCLC.  
 
2. Materials and methods 
2.1. Clinical samples and cell lines 
A total of lung cancer specimens comprising 12 SCLC, 47 NSCLC resected 
tumors, and 15 malignant pleural effusions in SCLC patients were retrieved from 
Okayama University Hospital, Okayama, Japan and NHO Yamaguchi-Ube Medical 
Center, Ube, Yamaguchi, Japan.  Each resected tumor was not treated with 
preoperative chemotherapy or radiotherapy.  Corresponding non-malignant tissue 
(peripheral lung or bronchial epithelium) of resected tumors were also available.  
Fifteen malignant pleural effusions were obtained from 8 patients who were treated by 
chemotherapy or radiotherapy and 7 patients who were not received any treatment.  All 
the specimens were frozen with liquid nitrogen immediately after surgery and stored at 
-80 °C.  Written informed consents were obtained from all the patients at two 
collection sites. 
Eleven SCLC cell lines [NCI-H1048 (H1048), SBC5, HCC33, NCI-H211 
(H211), NCI-H524 (H524), NCI-H841 (H841), NCI-H1688 (H1688), NCI-H1870 
(H1870), NCI-H2141 (H2141), NCI-H82 (H82), NCI-H249 (H249)] and 14 NSCLC 
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cell lines [PC-9, HCC827, NCI-H1975 (H1975), NCI-H3255 (H3255), A549, 
NCI-H1395 (H1395), NCI-H522 (H522), NCI-H838 (H838), HCC15, NCI-H125 
(H125), NCI-H460 (H460), NCI-H661 (H661), NCI-H1299 (H1299), NCI-H358 
(H358)] were used in this study.  We also investigated the HBEC 5KT cell, established 
from non-malignant human bronchial cells.  Cell lines whose prefix is NCI-H- 
(abbreviated as H-) or HCC-, and HBEC 5KT were kindly provided by Dr. Adi F. 
Gazdar (The University of Texas Southwestern Medical Center at Dallas, Dallas, TX).  
SBC5 was obtained from Drs. M. Tanimoto and K. Kiura (Okayama University, 
Okayama, Japan).  PC-9 was obtained from Immuno-Biological Laboratories 
(Takasaki, Gunma, Japan).  A549 was obtained from American Type Culture 
Collection (Manassas, VA).  All the cell lines except for HBEC 5KT were maintained 
in RPMI-1640 medium (Sigma-Aldrich, St. Louis, MO) supplemented with 10 % fetal 
bovine serum (FBS) and incubated at 37 °C in a humidified atmosphere with 5 % CO2.  
HBEC 5KT cell line was maintained in Keratinocyte-SFM (Invitrogen, Carlsbad, CA) 
with bovine pituitary extract (BPE) and human recombinant epidermal growth factor 
(EGF).  H82, H249, H1048, and SBC5 were treated with 5-aza-2’-deoxycytidine 
(DAC) (Sigma-Aldrich) at a concentration of 5-10 μM for 6 days, with medium changes 




2.2. Methylation specific PCR (MSP) assay 
Genomic DNA was extracted from cell lines and tissues by standard 
phenol-chloroform (1:1) extraction or by DNeasy Tissue Kit (Qiagen, Valencia, CA).  
DNA was subjected to bisulfate treatment using the EZ DNA Methylation Gold kit 
(Zymo Research Corp., Irvine, CA) according to the manufacturer’s protocol.  For 
malignant pleural effusions, genomic DNA was extracted using QIAamp Circulating 
Nucleic Acid kit (Qiagen) and bisulfite conversion was performed using Epitect 
Bisulfite kit (Qiagen) according to the manufacturer’s protocol.  The methylation 
statuses of miR-34a and 34b/c were determined by MSP assay using specific primers for 
the methylated and unmethylated forms [20].  The DNA from HBEC 5KT was treated 
with SssI methyltransferase (New England BioLabs, Beverly, MA) and was used as a 
positive control for methylated alleles.  PCR products were analyzed in 2 % agarose 
gels and stained with ethidium bromide.  
 
2.3. miR- 34s expression by quantitative RT-PCR 
The miRNA was isolated from cell lines and tissue specimens with TaqMan 
MicroRNA Cells-to-CTTM Kit (Ambion, Austin, TX) and mirVanaTMmiRNA Isolation 
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Kit (Ambion) and treated with DNase I (Ambion) to remove genomic DNA.  Reverse 
Transcriptional (RT) reaction was performed for extracted 0.5 μg miRNA with TaqMan 
MicroRNA Reverse Transcriptional Kit systems (Applied Biosystems, Foster City, CA) 
using TaqMan single RT primers for each miRNA (Applied Biosystems).  The 
quantitative RT-PCR for miR-34a, 34b, and 34c using TaqMan MicroRNA Assays 
technology (Perkin Elmer Corp., Foster City, CA) with the Step One Plus Real Time 
PCR systems (Applied Biosystems).  The miR-374 expression was used to normalize 
the expression of miR-34s as endogenous control of cell lines following manufacturer’s 
recommendation (www.appliedbiosystems.com). After normalization of miR-34s 
expression to miR-374, all relative expression values were defined as the ratios of the 
normalized miR-34s expression value of cell lines or primary tumors to that of HBEC 
5KT or individual non-malignant lung tissue, respectively. 
 
2.4. Immunohistochemistry for p53 expression 
Abnormality of p53 expression was examined using immunohistochemistry for 
primary tumors.  To detect the p53 protein, we used a monoclonal antibody against 
human p53 (DAKO-p53, DAKO, Denmark). The routinely formalin-fixed, 
paraffin-embedded tissue blocks were sectioned at a 4μm thickness. They were stained 
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by hematoxylin and eosin stain to confirm the presence and intensity of tumor cells and 
processed for immunohistochemistry (IHC).  Tissue sections were deparaffinized with 
xylene, rehydrated with graded ethanol, and immersed in Tris-buffered saline for IHC.  
For p53 scoring, more than ten randomly chosen high power fields were evaluated 
under an optical microscope and a trained pathologist was defined blindly scored.  In 
this study, p53 mutational status was defined as positive when more than 15 % of cells 
were positive regardless of the intensity as previously reported [21, 22]. 
 
2.5. Plasmid construction and gene transfection 
The miR-34b/c or scramble fragment as control was subcloned into pSilencer 
4.1-CMV neo Plasmid Vector (Ambion).  Four μg of pSilencer 4.1-CMV neo Vector 
was introduced into SCLC cell lines using LipofectamineTM 2000 Reagent (Invitogen).  
For experiments of transient transfection, cells were collected 72 hours after the 
transfection.  In order to establish stable transfectants, selection of the cells was started 
48 hours after the transfection in 6 cm dish with G418 (Invitrogen) antibiotics.  
Resistant clones were cloned after 3 weeks of selection. 
 
2.6. Colony formation assay for cell proliferation 
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The in vitro cell proliferation was tested by liquid colony formation assay.  
Fifty viable cells were plated onto 6-well plates in triplicate.  Cells were cultured and 
counted 14 days later after staining with 0.1 % crystal violet in 20 % ethanol for 5 
minutes at room temperature.  The number of visible colonies (> 50 cells) was 
counted. 
 
2.7. Cell migration and invasion assays 
Cell migration and invasion ability were established using a Boyden chamber 
assay with filter inserts (pore size, 8 μm) in 6-well plates (BD Biosciences Discovery 
Labware, Bedford, MA).  The cells in 2 ml serum-free RPMI1640 medium (300 μl 
containing 2.5 x 105 cells for transwell migration assay and 5 x 105 for Matrigel 
invasion assay) were added to the top chamber.  The bottom chamber was prepared 
with 10 % FBS as a chemoattractant. Non-invasive cells were removed by scrubbing 
with a cotton swab after 24-48 and 48-96 hours of incubation for migration assay and 
invasion assay, respectively.  The cells that had migrated through the membrane and 
stuck to the lower surface of the membrane were fixed and stained using Diff-Quik stain 
(Sysmex, Kobe, Japan).  For quantification of migration and invasion, the cells were 
counted under a microscope in 5 predetermined fields at x100 magnifications 
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representing the average of 3 independent experiments. 
 
2.8. Western blot analysis 
Cells were grown to 80 % confluency and harvested in lysis buffer [20 mmol/L 
Tris-HCl (pH 7.5), 150 mmol/L NaCl, 1 mmol/L Na2EDTA, 1 mmol/L EGTA, 1% 
Triton, 2.5 mmol/L sodium pyrophosphate, 1 mmol/L beta-glycerophosphate, 1 mmol/L 
Na3VO4, 1 μg/ml leupeptin] (Cell signaling Technology, Beverly, MA) supplemented 
with Complete, Mini (Roche, Basel, Switzerland) to extract protein.  Total 30 µg of 
protein were separated by SDS-PAGE and transferred to PVDF membranes.  The 
proteins on membranes were incubated overnight at 4 °C with the primary antibodies.  
We selected two molecules (c-METandCDK6).  The primary antibodies for western 
blotting are as follows: anti- MET (25H2, Cell Signaling), anti-phospho- MET (3D7, 
Tyr1234/1235; Cell Signaling), and anti-CDK6 (DCS83, Cell Signaling).  The 
following secondary antibodies were used: goat anti-rabbit or anti-mouse 
IgG-conjugated horseradish peroxidase (HRP) (Santa Cruz).  To detect specific signals, 
the membranes were detected by ECL plus Western Blotting Detection Reagents 




2.9. Statistical analysis 
Statistical analysis was performed using SPSS for Windows version 17.0 
(SPSS, Chicago, IL, USA).  All of the in vitro experiments were performed at least 
three times.  Data were represented as mean ± standard deviation.  The significance 
of the differences between two groups was determined using the chi-square test and the 
Mann-Whitney U-test, as appropriate.  A 5 % significance level (p < 0.05) was 
considered statistically significant.  
 
3.  Results 
3.1. Methylation and expression status of miR-34s  
We examined the methylation frequencies of miR-34a and b/c in 11 SCLC cell 
lines, 27 clinical samples consisting of 12 primary tumors and 15 malignant pleural 
effusions.  Usefulness of malignant pleural effusions to detect DNA methylation has 
been previously reported [23].  For comparison purposes, the methylation frequencies 
of miR-34a and b/c were also examined in 14 NSCLC cell lines and 47 primary tumors.  
Representative images of the electrophoresis results are shown in Figure 1.  MSP of 
the cell lines showed three PCR band patterns: only a methylated band, both a 
methylated and an unmethylated band, and only a methylated band.  The presence of 
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both methylated and unmethylated bands indicated partial methylation.  In this study, 
cell lines with partial methylation were classified as methylated cell lines.  The 
methylation of miR-34a and miR-34b/c was observed in 4 (36 %) and 7 (64 %) out of 
11 SCLC cell lines, respectively. Among the 27 SCLC clinical specimens, miR-34a and 
miR-34b/c were methylated in 4 (15 %) and 18 (67 %), respectively.  Stratified by 
specimens, miR-34a methylation was found in 3 of 12 SCLC tumors and 1 of 15 
malignant pleural effusions and miR-34b/c methylation was found in 9 of 12 tumors and 
9 of 15 malignant pleural effusions.  There was no significant difference in frequency 
of methylation between resected tumors and malignant pleural effusion specimens.  In 
addition, no significant difference was found in the frequencies of miR-34 methylation 
between previously treated 8 pleural effusions (0 % in miR-34a and 75 % in miR-34b/c) 
and 7 pleural effusions without any treatment (14 % in miR-34a and 57 % in 
miR-34b/c), respectively.  Among the NSCLC tumors, miR-34a and miR-34b/c 
methylation were observed in 5 (36 %) and 3 (21 %) cell lines and in 13 (28 %) and 12 
(26%) primary tumors, respectively.  The frequency of miR-34b/c methylation was 
significantly higher among the SCLC primary tumors than among the NSCLC samples 




3.2. Relationship between methylation and expression in SCLC 
The expressions of miR-34a, 34b, and 34c in 11 SCLC cell lines and 6 available 
SCLC primary tumors (4 methylated and 2 unmethylated cases) were examined using 
quantitative RT-PCR (Tables I, II).  The expression values of the miR-34s were defined 
as the ratio of the normalized expression value of SCLC cell lines to that of HBEC 5KT 
and that of the primary SCLC tumors to that of individual non-malignant lung tissue 
with arbitrarily assigned values of 1, respectively.  As shown in Table I and II, all 
expression values of miR-34s in SCLC cell lines and primary tumors were lower than 
their normal control samples (HBEC 5KT and non-malignant lung tissue).  The 
expressions of the miR-34b and 34c were significantly lower in the methylated cell lines 
than in the unmethylated cell lines (miR-34b, p = 0.011; miR-34c, p = 0.008).  
Regarding miR-34a, no significant difference or tendency was detected (p = 0.107).  
This finding may reflect the small sample sizes or the presence of partially methylated 
cells.  One cell line (H2141) with unmethylated miR-34a had very low expression 
value (0.05) for miR-34a, suggesting the presence of an alternative mechanism for gene 
silencing.   
We also treated 4 cell lines with DAC and found that the expressions of the 
miR-34s were restored in the methylated SCLC cell lines but not in the unmethylated 
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cell lines (Table III).  
 
3.3.p53 status in SCLC 
p53 is a transcriptional factor for miR-34s. Thus, we examined the correlation 
between the p53 status and the expressions of miR-34s (Table II).  Genotyping data for 
the TP53 gene in H1048, SBC5, H211, H524, H841, H2141, H82, and H249 were 
queried from the database of the International Agency for Research on Cancer (IARC) 
version 15 (www-p53.iarc.fr) to find that all cell lines harbor TP53 mutation.  HCC33 
and H1870 also harbor mutation (HCC33, C242Y and H1870, Y234C) and these data 
were provided by Dr. Adi F. Gazdar (University of Texas Southwestern Medical Center 
at Dallas, Dallas, TX, USA).  The mutation status of H1688 was not available.  As a 
result, 10 out of 11 cell lines were found to carry TP53 mutations.  The p53 status of 
the primary tumors was determined using immunohistochemistry [21, 22].  The 
aberrant positive expression of p53 protein was regarded as a p53 abnormality 
(mutation) in the primary cancers.  Four (67 %) out of the 6 primary SCLC tumors 
exhibited positive p53 immunohistochemistry results suggesting the presence of p53 
mutation.  The relationship between the p53 alterations and the expressions of miR-34s 
was examined, but no correlation between the p53 status and the expressions of 
17 
 
miR-34s was found. 
 
3.4. Impact of miR-34b/c on cell proliferation 
Because the frequency of methylation was higher in miR-34b/c and because 
miR-34a methylation in SCLC cell lines was mainly partial methylation but miR-34b/c 
was heavily methylation, we focused on miR-34b/c for a functional analysis.  For this 
purpose, we established stable transfectans with miR-34b/c and scramble controls for 
H1048 and SBC5.  To examine the anti-proliferative effect of miR-34b/c induction, we 
performed a colony formation assay for stable transfectants.  Cell proliferation was 
significantly inhibited in the SCLC cells transfected with miR-34b/c, compared with 
that in the cells that were transfected with a scramble control (50 % inhibition for 
H1048, p = 0.001; 44 % for SBC5, p< 0.001) (Fig.2). 
 
3.5. Impact of miR-34b/c on cell migration and invasion 
To estimate the effect of introducing miR-34b/c on the migration and invasion 
potential of SCLC, cell migration and invasion potential were examined using a Boyden 
chamber.  Microscopy images of the Boyden chamber assay are shown in Figure 3.  
Migration and invasion were significantly suppressed in miR-34b/c transfectants, 
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compared with control transfectants (migration: 50 % inhibition for H1048, p = 0.051; 
54 % for SBC5, p = 0.044; invasion: 33 % inhibition for H1048, p = 0.002; 30 % 
inhibition for SBC5, p = 0.012).  
 
3.6. Protein expression of stable transfectants 
To examine the effect of miR-34b/c introduction, we focused on c-MET (both total 
and phosphorylated types) and CDK6 which were the putative target of miR-34b/c.  Western 
blotting was carried out in SCLC stable transfectants.  Total and phosphorylated c-MET and 
CDK6 expressions were down-regulated in the SCLC cell lines examined.  CDK6 tended to 




In this study, we found that miR-34b/c methylation was a frequent alteration of 
SCLC.  As a result, miR-34b/c expression was reduced in SCLC, causing tumor cell 
proliferation and invasiveness.  Our results also indicated that miR-34b/c methylation 
is the early event for tumorigenesis of SCLC because there was no difference in 
frequency between surgically resected tumors supposed to be early stage and malignant 
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pleural effusions considered to be advanced stage.  In addition to lung cancer, 
miR-34b/c methylation has been reported in various kinds of malignant tumors 
including colorectal and ovarian cancers [20, 24].  We previously reported the 
methylation and function of miR-34b/c in malignant pleural mesothelioma [25]; the 
same established methodology was also used in the present study.  p53 is a 
transcriptional factor for miR-34s.  The p53 mutation has been reported in various 
cancers, including lung cancer.  However, the effect of p53 mutation on the expression 
and methylation of miR-34b/c remains uncertain.  In ovarian cancer, miR-34a 
methylation and p53 mutation are not associated.  Corney and associates reported that 
no direct correlation was observed between miR-34 methylation status and miR-34 
expression levels.  In addition, p53 mutation has no effect on miR-34b/c methylation 
in ovarian cancer [24].  In the SCLC cell lines that were examined in the present study, 
10 out of 11 cell lines carried a p53 mutation, but the expression levels of the miR-34s 
varied and were correlated with the methylation status.   In primary tumors, while the 
p53 mutational status was determined using immunohistochemistry [21, 22], the 
relationship among the expression and methylation of miR-34b/c and p53 mutation was 
similar to that in the cell lines.   Our data suggest that miR-34 expression was not 
completely silenced in the p53-altered cases and that methylation may contribute more 
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strongly to the expressions of miR-34s.    
Antitumor effects, including the inhibition of cell proliferation, migration, and 
invasion, were observed with the introduction of miR-34b/c.  In general, miRNA has 
multiple target mRNAs, and c-Met is a well-known target molecule of miR-34b/c [16, 
17].  c-Met and its ligand hepatocyte growth factor (HGF) have been shown to be 
involved in cell proliferation, invasion, and angiogenesis [26, 27].  A previous study 
found that the c-Met/HGF pathway was functional in SCLC, indicating in vitro that the 
c-MET/HGF axis may be a promising target for SCLC [27, 28].  Our results, together 
with those of previous reports, strongly suggest that miR-34b/c plays an important role 
in the pathogenesis of SCLC and may be a useful therapeutic target for SCLC.  
In SCLC, the methylation of miR-34a was not a frequent event compared with 
that of miR-34b/c, but its expression was low compared with that in non-malignant lung 
tissue. The degree of reduction in miR-34a expression was similar to that of miR-34b/c 
in some SCLC cell lines, suggesting that miR-34a silencing may also be involved in the 
pathogenesis of SCLC, although the mechanism of silencing has not been clearly 
elucidated.  Further study on the role of miR-34a in SCLC is warranted.   
In conclusion, our findings showed that miR-34b/c is more frequently 
methylated in SCLC than in NSCLC, resulting in the down-regulation of miR-34b/c.  
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As this alteration confers a growth and invasion advantage to cancer cells, targeting 
miR-34b/c is a potential therapeutic option for the treatment of SCLCs.  The targeting 
of SCLCs is of particular interest, as recent trials of targeted drugs for lung cancer have 
focused mainly on NSCLCs.  
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Figure 1.    Methylation status of miR-34a and 34b/c in SCLCs. Representative 
examples of conventional methylation specific PCR for miR-34a and 34b/c in SCLC 
cell lines (A) and primary tumors (B). The unmethylated form of miR-34s was always 
found in primary tumors that had been grossly dissected and thus had at least some 
contamination with normal cells. M, methylated; U, unmethylated; POC, positive 
control (Sss1 treated DNA). 
 
Figure 2.    Colony formation assays of SCLC cell lines stably transfected with 
miR-34b/c (p-miR-34b/c) or control (p-scramble) plasmid vectors. 
A, Representative results of colony formation assays carried out using the indicated 
SCLC cell lines are shown.  B, Relative colony formation efficiencies are presented. 
Shown are means of three replications; error bars represent standard deviations. 
 
Figure 3.    The impact of miR-34b/c introduction on SCLC cell migration and 
invasion potential. 
The miR-34b/c inhibits cell migration (A) and invasion (B) of the SCLC cells. Migrated 
or invaded cells were fixed and stained, and representative examples are shown above. 
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The quantitative values expressed as the means ± SD of five microscopic fields are 
representative of two separate experiments (below). 
 
Figure 4  Protein expression profile of SCLC cell lines in stable transfection of 








Table I  
The relative expressions and methylation status of miR-34s in 11 SCLC cell lines. 
 
 
Mut, mutation; Wt, wild type; NA, not available; M, methylated; U, unmethylated;  
M/U, partially methylated  





Table II  
The relative expressions and methylation status of miR-34s in 6 available SCLC primary tumors.  
 
  
LD, limited disease; ED, extensive disease; Mut, mutation; Wt, wild type; NA, not available; M, methylated; U, unmethylated  
*, p53 mutational status is as positive if more than 15 % of nuclei are stained.   
**, miR-34s relative expression values are relative expression values compared with those of each non-malignant tissue, which are 






Table III  
The fold change of miR-34s expression after DAC treatment. 
 
 
M, methylated; U, unmethylated; M/U, partially methylated  
Increase of miR-34a and miR-34b/c expression in SCLC cell lines with methylation after 5-aza-2’-deoxycytidine (DAC) treatment. The 
expression ratio shows the relative miR-34s expression values in DAC-treated cell lines compared with the miR-34s expression values in 
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